###begin article-title 0
Complex organisation and structure of the ghrelin antisense strand gene GHRLOS, a candidate non-coding RNA gene
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 305 311 305 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 385 389 385 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL</italic>
###xml 421 427 421 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
The peptide hormone ghrelin has many important physiological and pathophysiological roles, including the stimulation of growth hormone (GH) release, appetite regulation, gut motility and proliferation of cancer cells. We previously identified a gene on the opposite strand of the ghrelin gene, ghrelinOS (GHRLOS), which spans the promoter and untranslated regions of the ghrelin gene (GHRL). Here we further characterise GHRLOS.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 18 25 18 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 137 141 137 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL</italic>
###xml 149 156 149 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 221 226 221 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 291 298 291 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 393 407 393 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2-GHRLOS </italic>
###xml 445 452 445 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 540 547 540 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 637 643 637 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13 </italic>
###xml 722 729 722 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 838 845 838 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1008 1015 1008 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1303 1308 1303 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
We have described GHRLOS mRNA isoforms that extend over 1.4 kb of the promoter region and 106 nucleotides of exon 4 of the ghrelin gene, GHRL. These GHRLOS transcripts initiate 4.8 kb downstream of the terminal exon 4 of GHRL and are present in the 3' untranslated exon of the adjacent gene TATDN2 (TatD DNase domain containing 2). Interestingly, we have also identified a putative non-coding TATDN2-GHRLOS chimaeric transcript, indicating that GHRLOS RNA biogenesis is extremely complex. Moreover, we have discovered that the 3' region of GHRLOS is also antisense, in a tail-to-tail fashion to a novel terminal exon of the neighbouring SEC13 gene, which is important in protein transport. Sequence analyses revealed that GHRLOS is riddled with stop codons, and that there is little nucleotide and amino-acid sequence conservation of the GHRLOS gene between vertebrates. The gene spans 44 kb on 3p25.3, is extensively spliced and harbours multiple variable exons. We have also investigated the expression of GHRLOS and found evidence of differential tissue expression. It is highly expressed in tissues which are emerging as major sites of non-coding RNA expression (the thymus, brain, and testis), as well as in the ovary and uterus. In contrast, very low levels were found in the stomach where sense, GHRL derived RNAs are highly expressed.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 301 308 301 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
GHRLOS RNA transcripts display several distinctive features of non-coding (ncRNA) genes, including 5' capping, polyadenylation, extensive splicing and short open reading frames. The gene is also non-conserved, with differential and tissue-restricted expression. The overlapping genomic arrangement of GHRLOS with the ghrelin gene indicates that it is likely to have interesting regulatory and functional roles in the ghrelin axis.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 879 885 879 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 959 963 959 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL</italic>
###xml 966 967 966 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1047 1054 1047 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1106 1113 1106 1113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1168 1175 1168 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
Ghrelin, a hormone with many physiological and pathophysiological roles, was initially described as the endogenous ligand for the growth hormone secretagogue receptor (GHSR 1a), through which it stimulates the release of growth hormone from the anterior pituitary [1]. Ghrelin is primarily produced in the stomach and plays a key role in regulating appetite, gut motility and energy balance [2-6]. Ghrelin is also an autocrine factor in a number of tissues, as it regulates insulin release and has therapeutic potential for inflammatory diseases, heart disease, cancer cachexia, diabetes mellitus and obesity [7]. Despite the importance of ghrelin in a range of physiological systems and pathophysiological conditions, little is known about the regulation of ghrelin synthesis and secretion. We previously identified a gene on the opposite strand of the ghrelin gene, ghrelinOS (GHRLOS), which spans the promoter and untranslated regions of the ghrelin gene (GHRL) [8]. However, the genomic structure, expression pattern and potential function of GHRLOS remains to be investigated. It is not known whether GHRLOS RNA species with open reading frames exist, or whether GHRLOS is a non-coding RNA gene.
###end p 9
###begin p 10
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 141 146 <span type="species:ncbi:9606">human</span>
###xml 451 457 <span type="species:ncbi:9606">humans</span>
There is strong support for the hypothesis that antisense transcripts provide a widespread and important mechanism for the regulation of the human genome [9,10]. Our understanding of the genome is currently undergoing a paradigm shift, as a previously hidden and complex layer of antisense and non-coding RNAs is emerging, which controls gene transcription and translation through a diverse range of mechanisms [11]. Much phenotypic diversity between humans and other species is likely to be due to regulation by RNA [12].
###end p 10
###begin p 11
###xml 69 75 69 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 96 103 96 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 278 285 278 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 394 401 394 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 413 422 413 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico</italic>
###xml 439 446 439 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 568 575 568 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
In this study, we examined the genomic structure and organisation of GHRLOS. We have found that GHRLOS spans approximately 44 kb of genomic DNA and transcribes long, 5' capped, polyadenlyated RNA species that are extensively spliced and differentially expressed. High levels of GHRLOS expression occur in the emerging non-coding RNA tissues, the brain, testis and thymus. We have also examined GHRLOS RNA species in silico, revealing that GHRLOS is a candidate non-coding RNA gene. These data provide a strong basis for further functional studies to determine whether GHRLOS plays a role in the regulation of ghrelin gene expression.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
Characterisation of GHRLOS start sites and alternative splicing
###end title 13
###begin p 14
###xml 49 56 49 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 132 139 132 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 419 426 419 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 453 454 453 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 544 545 544 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 740 747 740 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 923 924 923 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 981 982 981 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1046 1053 1046 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 1132 1134 1132 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1183 1189 1183 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 1255 1261 1255 1261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 163 168 <span type="species:ncbi:9606">human</span>
An initial aim of this study was to characterise GHRLOS in a range of tissues. As we have previously demonstrated the expression of GHRLOS mRNA transcripts in the human stomach [8], we performed 5' RLM-RACE (RNA ligase mediated rapid amplification of cDNA ends) on this tissue. Unexpectedly, we identified a number of new exons (exon I-III) [GenBank:, , and ] that are 2.5 to 4.8 kb upstream of the previously reported GHRLOS transcription start sites [8] in exon 4* (4*a-c). To simplify the numbering of GHRLOS exons, the previously reported [8] exons 4*, 2**, 2* and -1* have been renamed exon 1 to 4, respectively; while the exons upstream of the reported start sites in exon 1 are denoted by Roman numerals (I-III). Importantly, in the GHRLOS variants demonstrated via 5' RLM-RACE, exon 1 is extended, with a 106 nt region (exon 1d, hereafter termed exon 1) overlapping exon 4 of the ghrelin gene (see [Additional file 1]). The novel first exon, exon I, is 51 bp in size (Fig. 1) and overlaps the 3' untranslated region of the adjacent gene, TATDN2 (TatD DNase domain containing 2, also known as hypothetical protein KIAA0218) [13]. This gene initiates on the same DNA strand as GHRLOS, approximately 32,000 base pairs upstream of the 51 bp exon I of GHRLOS.
###end p 14
###begin p 15
###xml 11 18 11 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mapping of <italic>GHRLOS </italic>transcript 5' and 3' ends</bold>
###xml 89 96 89 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 288 295 288 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 327 334 327 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 461 468 461 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
Mapping of GHRLOS transcript 5' and 3' ends. Relative positions of the 5' and 3' ends of GHRLOS transcripts were derived from RACE, inverse PCR and cDNA primer walking RT-PCR experiments, as well as from publically available data from EST databases, Affymetrix exon arrays and CAGE tags. TATDN2 exons are shown as white boxes, GHRLOS exons as black boxes, introns as horizontal lines. Size (bp) of selected exons are shown above each exon. All known 3' ends of GHRLOS transcripts contain the same polyadenylation signal. Poly(A) tails are represented by AAAA. Cap-analysis gene expression (CAGE) tags are indicated by arrows, and CAGE-aided cDNA primer walking amplicons are displayed below the arrows. Not drawn to scale.
###end p 15
###begin p 16
###xml 53 60 53 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 501 502 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1435 1441 1435 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 1162 1167 <span type="species:ncbi:9606">Human</span>
In order to determine the polyadenylation site(s) of GHRLOS transcripts, 3' RACE and inverse PCR were conducted using normal stomach and prostate tissues, the RWPE-1 prostate cell line and the PC3 prostate cancer cell line (which is derived from prostate cancer cells that have metastasised to the bone). We obtained 3' RACE clones from the PC3 prostate cancer cell line, which demonstrated a 1.4 kb exon 4a and a 1.1 kb exon 4b, with the putative polyadenylation signal AAATTA [GenBank:, and ] (Fig. 1). The 3' RACE data matches a number of Expressed Sequence Tags (ESTs) from subchondral bone [GenBank:], foetal liver [GenBank:], pooled liver and spleen [GenBank:; ], Wilms' tumour (a paediatric cancer of the kidney) [GenBank:], pooled brain cancers [GenBank:] and high grade serous carcinoma of the uterus [GenBank:]. Moreover, we performed uncapped inverse PCR, and sequencing of amplicons from the PC3 cell line revealed a 90 bp exon I and exon 4 sequence with a 3' end differing by less than 20 base pairs when compared to the 3' RACE and reported ESTs [GenBank:]. Interestingly, the putative 3' end of exon 4 corresponds to publicly available Affymetrix Human Exon 1.0 ST array data (Exon Cluster ID 183613). Furthermore, all of the amplicons that we obtained were followed by a stretch of adenosines at the 3' ends that are not present in the genomic sequence. We, therefore, concluded that we had reached a genuine 3' end of GHRLOS.
###end p 16
###begin title 17
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
Complex pattern of GHRLOS variant exon expression
###end title 17
###begin p 18
###xml 56 63 56 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 227 233 227 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 449 456 449 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 584 585 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 772 779 772 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 125 130 <span type="species:ncbi:9606">human</span>
###xml 154 159 <span type="species:ncbi:9606">human</span>
###xml 327 332 <span type="species:ncbi:9606">human</span>
In order to examine the size and tissue distribution of GHRLOS transcripts, we performed Northern blot analysis of mRNA from human stomach and 12 normal, human tissues. With a riboprobe designed to span exons I, II, 1 and 2 of GHRLOS, a weak, smeared signal ranging from approximately 1.0 to 2.0 kb in size was observed in the human stomach upon a lengthened exposure time (data not shown). A riboprobe spanning exon 1 alone (a region common to all GHRLOS RNA isoforms) resulted in signals ranging from 1.0 to 5.5 kb in size in the pancreas, prostate, salivary gland and thymus (Fig. 2). Upon longer exposure times, a smear in the 1.0 to 5.5 kb range was seen in all tissues, except for peripheral blood leukocytes and urinary bladder (data not shown). This suggests that GHRLOS is a fully processed transcript consisting of many mRNA isoforms.
###end p 18
###begin p 19
###xml 24 26 24 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 101 0 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Northern blot of poly(A)<sup>+ </sup>RNA from normal, human tissues with strand-specific, DIG-labelled riboprobe</bold>
###xml 133 135 132 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 228 235 227 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 43 48 <span type="species:ncbi:9606">human</span>
Northern blot of poly(A)+ RNA from normal, human tissues with strand-specific, DIG-labelled riboprobe. Northern blot of 2 mug poly(A)+ RNA from 12 normal tissues (OriGene) probed for exon 1, which is an exon common to all known GHRLOS mRNA isoforms (top panel). The position of the RNA size markers is indicated (RNA Millennium Markers, OriGene). A pound mark (#) indicates a putative 1.7-1.8 kb (approximately 2.0 kb with polyadenylation tail) full-length transcript in the prostate, as deduced from RLM-RACE and RT-PCR experiments. Several other transcripts 1-5.5 kb in size could be seen. The same membrane was stripped and hybridized with a beta-actin cRNA probe as a loading control (bottom panel).
###end p 19
###begin title 20
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
GHRLOS exons are highly polymorphic
###end title 20
###begin p 21
###xml 73 80 73 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 223 230 223 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 548 555 548 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 565 572 565 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 717 718 717 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 899 906 899 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 928 929 928 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1021 1023 1021 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1045 1052 1045 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1224 1226 1224 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1229 1236 1229 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1296 1297 1296 1297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 286 291 <span type="species:ncbi:9606">human</span>
The RACE, inverse RT-PCR and Northern blotting experiments indicate that GHRLOS is extensively spliced and that isoforms range greatly in size (from approximately 1.0-5.5 kb). To examine the alternative splicing pattern of GHRLOS in greater detail, we performed RT-PCR using a range of human tissues and cell lines. We used a forward primer common to exon Ia (identified via 5' RLM-RACE) and a reverse primer in a region common to exons 4a and b. Sequence analysis indicated that, with the exception of exons 1 and 4, which are common to all known GHRLOS isoforms, GHRLOS exons are highly polymorphic in size and exon skipping occurs frequently. A representative amplicon banding pattern is shown in [Additional File 2]. The highly variable splicing pattern revealed by RT-PCR is consistent with the diffuse and broad signal which we detected by Northern blotting. In total we obtained 13 different GHRLOS splice variants (Fig. 3). Analysis using GMAP, a genomic mapping and alignment program for mRNA and EST sequences [14], indicated that all GHRLOS exons are flanked by canonical splice donor and acceptor sites (GT/AG), except for exons 3a and 3c where the splice junction is the common non-canonical splice pair GC/AG [15]. GHRLOS exons and introns identified are listed in [Additional File 3].
###end p 21
###begin p 22
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Complex pattern of GHRLOS variant exon expression</bold>
###xml 51 58 51 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
Complex pattern of GHRLOS variant exon expression. GHRLOS transcripts A to M were demonstrated by RT-PCR, while the 5' end (exon I) and 3' end (exon 4) were determined by RACE, inverse PCR and by examining publically available Affymetrix exon array data and expressed sequence tag (EST) data. Exons are represented as boxes, introns as horizontal lines and sizes (bp) are indicated below each exon. The size of exon 4a is listed as 1377-1388 and corresponds to a transcript which is polyadenylated 20-30 bp from the same polyadenylation signal (data not shown). Exon 4b harbours the same polyadenlation site, but is 5' truncated (250 bp). GhrelinOS variants A to M have been deposited to GenBank: A-F, stomach [GenBank:, , , , , and ]; G-H, prostate [GenBank:, and ]; I, foetal brain [GenBank:]; J-M, heart [GenBank:, , , and ].
###end p 22
###begin title 23
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
Extending the known length of GHRLOS
###end title 23
###begin p 24
###xml 31 38 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 177 184 177 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 427 428 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 447 454 447 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 538 544 538 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2</italic>
###xml 679 686 679 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 880 882 880 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 883 885 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1101 1103 1101 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1143 1149 1143 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 1445 1451 1445 1451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 1522 1529 1522 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1750 1751 1750 1751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1773 1774 1773 1774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 2082 2089 2082 2089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 2132 2138 2132 2138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2</italic>
###xml 2163 2170 2163 2170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 2259 2261 2259 2261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
Northern blotting demonstrated GHRLOS transcripts 1-5.5 kb in size, however, further RT-PCR and 3' RACE analysis with a number of different primer combinations failed to reveal GHRLOS transcripts larger than 2 kb (data not shown). For this reason, we hypothesised that the ghrelin antisense gene may extend further upstream. Capped RLM-RACE of stomach tissue and uncapped inverse PCR of the PC3 prostate cancer cell line (Fig. 1) indicated that a GHRLOS promoter (exon I) was present at the very end of the 2 kb 3' untranslated exon 8 of TATDN2. Moreover, we discovered that multiple Cap Analysis of Gene Expression (CAGE) tags are clustered approximately 1.5 kb upstream of the GHRLOS transcription start sites found via 5' RLM-RACE. CAGE tags are an average of 20-21 nucleotides and are produced by large-scale sequencing of concatemers derived from the 5' ends of capped mRNA [16,17]. The CAGE method, therefore, detects the most 5' site of the mRNA transcripts (the transcription start site) and gives an unbiased and comprehensive picture of the positions and usage of transcription start sites [18]. To confirm if this region belongs to GHRLOS, we employed nested RT-PCR using thymus tissue, foetal brain tissue and Hep G2 hepatocarcinoma cell line cDNA (with RNA reverse transcribed using oligo(dT) primers). The forward primers were present immediately downstream of the CAGE tag cluster (which is 1.5 kb upstream of the 51 bp exon I of GHRLOS) and the reverse primers spanned exon 1 (which is common to all known GHRLOS variants). Sequence analysis revealed several novel exon I variants, which were approximately 1601 bp, 994 bp and 526 bp in length. All of these variants spliced into the expected acceptor site of the 106 bp exon 1 (Fig. 1 and [Additional File 4]). The end of the 1601 bp exon I (termed exon Ib) spanned the 51 bp exon I (exon Ia) identified via capped RLM-RACE of the stomach, while the other exons (Ic-d) employed different upstream donor sites, suggesting that they are alternative first exons. The data demonstrate that there are at least two first GHRLOS exon regions in the untranslated region of TATDN2. This suggests that the GHRLOS promoter is a broad-type, TATA-less promoter that initiates transcription at many sites [19].
###end p 24
###begin p 25
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 80 86 80 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2</italic>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 466 473 466 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 546 552 546 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 654 661 654 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 809 816 809 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 830 837 830 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 991 1005 991 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2-GHRLOS </italic>
###xml 1047 1048 1047 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1397 1404 1397 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 1410 1411 1410 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1662 1664 1662 1664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
The length of GHRLOS transcripts initiating in exon I (present in the 3' UTR of TATDN2) is 1.3-3.6 kb, corresponding in size to the Northern data. However, the potential identity of the approximately 5.5 kb transcript seen in the Northern blot with a full-length, 106 nt exon 1 probe (Fig. 2) was not determined. After prolonged exposure of the Northern blot, the 5.5 kb transcript was observed in all tissues except the urinary bladder and uterus (data not shown). TATDN2 is only approximately 1 kb upstream of exon II and 4.5 kb from exon 1 of GHRLOS, suggesting that transcription-induced chimaeras (TICs) may be generated [20] and give rise to large GHRLOS transcripts. Because TICs must contain a first exon of the upstream gene [20], we employed primers in exon 2 (immediately after the start codon) of TATDN2 and exon 1 of GHRLOS (which was also the sequence of our Northern riboprobe). Using nested RT-PCR (on cDNA reverse transcribed using oligo(dT) primers), we isolated a 2831 bp TATDN2-GHRLOS amplicon from the thymus [GenBank:] (Fig. 4). This transcript has canonical splice donor and acceptor sites (GT/AG) and splices into the expected acceptor site of the 106 bp exon 1. This variant harbour significant open reading frames corresponding to the TATDN2 protein, but contains alternative exons and a premature termination codon more than 50 bp upstream of the final coding exon 7 of TATDN2 (Fig. 4). This is likely to result in degradation of the mRNA by nonsense-mediated RNA decay (NMD), a surveillance mechanism that detects and degrades mRNA that may encode truncated proteins with dominant-negative or deleterious gain-of-function activities [21].
###end p 25
###begin p 26
###xml 0 71 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Identification of a TATDN2-GHRLOS chimaeric transcript by nested RT-PCR</bold>
###xml 112 119 112 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 132 139 132 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 153 160 153 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 191 198 191 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 349 356 349 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 517 524 517 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 652 666 652 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2-GHRLOS </italic>
###xml 849 863 849 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2-GHRLOS </italic>
Identification of a TATDN2-GHRLOS chimaeric transcript by nested RT-PCR. (A) Overview of the gene structures of TATDN2 (orange) and GHRLOS exons (blue). TATDN2 exon 8 contains first exons of GHRLOS and is therefore shown in orange and blue. Exons are represented as boxes, introns as horizontal lines and sizes (bp) are indicated below each exon. A TATDN2 CpG island is shown as a green box. The location of RT-PCR primers employed to detect chimaeras are shown below each exon as arrows. The reported 761 amino acid TATDN2 open reading frame (encoded by [GenBank:]) is shown as a straight line (M = initiating methionine; * = stop codon). A chimaeric TATDN2-GHRLOS transcript, its open reading frame and locations of a premature stop codon (*) is shown. Not drawn to scale. (B) Ethidium bromide stained agarose gel of nested RT-PCR product for the TATDN2-GHRLOS chimaera. Arrows indicates the amplicon schematically displayed in (A). M = 1 kb DNA Ladder (NEB).
###end p 26
###begin p 27
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 79 86 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 116 123 116 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 178 185 178 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 189 195 189 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 253 260 253 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 287 294 287 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 351 357 351 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 400 406 400 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2</italic>
We have identified several novel GHRLOS transcripts. This includes overlapping GHRLOS transcripts initiating in the TATDN2 3' UTR and putative transcription-induced chimaeras of TATDN2 and GHRLOS. These findings extend the previously reported length of GHRLOS by ~37 kb. We propose that GHRLOS harbour several promoters with start sites in exon 1 (of GHRLOS), and in the 3' UTR and the first exon of TATDN2.
###end p 27
###begin title 28
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
Results of in silico analysis indicate that GHRLOS is a non-coding RNA gene
###end title 28
###begin p 29
###xml 21 28 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 52 66 52 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2-GHRLOS </italic>
###xml 165 172 165 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 309 316 309 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 448 455 448 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 487 494 487 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 601 602 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 775 776 775 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 873 879 873 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 1108 1115 1108 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1131 1132 1131 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 1237 1238 1237 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
###xml 1368 1375 1368 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1437 1444 1437 1444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 418 423 <span type="species:ncbi:9606">human</span>
###xml 569 574 <span type="species:ncbi:10090">mouse</span>
###xml 579 582 <span type="species:ncbi:10116">rat</span>
###xml 888 893 <span type="species:ncbi:10090">mouse</span>
###xml 1075 1082 <span type="species:ncbi:9031">chicken</span>
###xml 1102 1107 <span type="species:ncbi:9606">human</span>
###xml 1206 1211 <span type="species:ncbi:9606">human</span>
###xml 1216 1219 <span type="species:ncbi:9615">dog</span>
###xml 1354 1357 <span type="species:ncbi:9615">dog</span>
###xml 1362 1367 <span type="species:ncbi:9606">human</span>
Sequence analysis of GHRLOS (excluding the putative TATDN2-GHRLOS transcription-induced chimaeras that are likely to result in nonsense mediated decay) reveals that GHRLOS transcripts do not harbour protein coding potential, but rather have several features of non-coding RNA genes. GMAP analysis showed that GHRLOS spans approximately 44 kb on 3p25.3 (data not shown). The Mulan sequence conservation profile for the human and putative vertebrate GHRLOS orthologues indicated that most GHRLOS exons (I, II, III, 2, 3) are not highly conserved compared to the putative mouse and rat orthologues (Fig. 5). The 106 bp exon 1 (which spans exon 4 of the ghrelin gene) and approximately 90 bp of the 1.4 kb exon 4 (which spans exon -1 of the ghrelin gene) are conserved, however [8]. RT-PCR experiments revealed no evidence for antisense transcription from exon I to exon 1 (of GHRLOS) in the mouse (data not shown), suggesting that ghrelin antisense transcription (at these specific locations) may not be conserved. Furthermore, there is very low sequence similarity between the chicken, frog, opossum and human GHRLOS sequences (Fig. 5). Interestingly, exons II, 2 and 3 appear to be highly conserved between human and dog [Additional File 5], with 70-75% homology for exons 2 and 3. However, no significant open reading frames (ORFs) are conserved between dog and human GHRLOS sequence (data not shown). Taken together, this suggests that GHRLOS has evolved rapidly and may be unique to primates.
###end p 29
###begin p 30
###xml 0 62 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mulan sequence conservation profile for vertebrate GHRLOS loci</bold>
###xml 320 327 320 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 602 609 600 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 644 651 642 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 117 122 <span type="species:ncbi:9606">human</span>
###xml 136 143 <span type="species:ncbi:9031">chicken</span>
###xml 205 210 <span type="species:ncbi:10090">mouse</span>
###xml 223 226 <span type="species:ncbi:10116">rat</span>
###xml 239 242 <span type="species:ncbi:9615">dog</span>
###xml 259 273 <span type="species:ncbi:9544">rhesus macaque</span>
###xml 294 304 <span type="species:ncbi:9598">chimpanzee</span>
###xml 628 633 <span type="species:ncbi:9606">human</span>
Mulan sequence conservation profile for vertebrate GHRLOS loci. The horizontal axis displays the input sequence from human (UCSC hg18), chicken [UCSC galGal3], frog [UCSC xenTro2], opossum [UCSC monDom4], mouse [UCSC mm9], rat [UCSC rn4], dog [UCSC canFam2], rhesus macaque [UCSC rheMac2], and chimpanzee [UCSC PanTro2] GHRLOS loci. Evolutionary conserved regions (ECRs, > 70% identity; >/= 99 bp) are depicted as dark red bars above each pairwise alignment. Exons (blue), intergenic elements (red) and intron sequence (pink) are marked and the vertical axis shows the percent similarity of vertebrate GHRLOS orthologues to the human sequence. GHRLOS exon numbers are shown. A transposable element in exon 4 (MIR3#SINE/MIR) is shown above exon 4.
###end p 30
###begin p 31
###xml 24 31 24 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 52 62 52 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In silico </italic>
###xml 106 113 106 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 385 392 385 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 599 600 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Our study suggests that GHRLOS is a non-coding RNA. In silico translation revealed that the heterogeneous GHRLOS RNAs contain multiple stop codons, resulting in lack of extensive reading frames, and the putative ORFs do not span conserved regions (data not shown). Moreover, no significant sequence similarity to any known proteins was observed (data not shown). Finally, screening of GHRLOS sequence against a reference collection of repeats (RepbasE) using CENSOR [22] identified a 203 bp overlap of exon 4 with the extinct 224 bp MIR3 SINE element, which is present in all vertebrates [23] (Fig. 5). Interestingly, the presence of repeat elements in exons of non-coding RNAs has been reported previously [24-27]
###end p 31
###begin title 32
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
The GHRLOS terminal exon 4 and a putative SEC13 exon overlap in an antisense manner
###end title 32
###begin p 33
###xml 34 41 34 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 117 123 117 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13 </italic>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S6">6</xref>
###xml 196 202 196 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13 </italic>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 389 394 389 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13</italic>
###xml 459 465 459 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13 </italic>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 658 664 658 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13 </italic>
###xml 690 697 690 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T</italic>
###xml 700 708 700 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T </italic>
###xml 788 793 788 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13</italic>
###xml 925 927 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6C</xref>
###xml 932 934 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6D</xref>
###xml 980 988 980 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T </italic>
###xml 1065 1073 1065 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T </italic>
###xml 1110 1115 <span type="species:ncbi:9606">human</span>
We have discovered that exon 4 of GHRLOS is also on the opposite strand of a novel terminal exon of the neighbouring SEC13 gene in a tail-to-tail, 3' to 3', fashion (Fig. 6A) [Additional File 6]. SEC13 plays an important role in protein transport and is a component of the COPII complex [28,29]. BLAST analysis identified a brain tumour EST [GenBank:] [30], which contains exon 7 and 8 of SEC13, as well as 206 bp sequence corresponding to a novel exon 9b of SEC13 10.7 kb upstream of exon 8. We verified the expression of this EST by RT-PCR (using cDNAs reverse transcribed with oligo(dT) primers) (Fig. 6B) and by sequencing [GenBank:]. We have named this SEC13 variant, SEC13-tentative (SEC13-T). SEC13-T may encode a 372 amino acid protein. The first 285 amino acids are identical to SEC13, while the normal C-terminal 37 amino acids have been replaced by 87 amino acids encoded by the alternative terminal exon 9b (Fig. 6C and 6D). The putative C-terminal-coding exon of the SEC13-T isoform appears to be conserved only in primates (data not shown). Therefore SEC13-T alternative splicing is likely to be human-specific or primate-specific.
###end p 33
###begin p 34
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC1</italic>
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T</italic>
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>GHRLOS </italic>overlaps a putative <italic>SEC1</italic>3 isoform, <italic>SEC13-T</italic>, in an antisense manner</bold>
###xml 110 123 110 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS, SEC13</italic>
###xml 137 143 137 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13 </italic>
###xml 175 181 175 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13T</italic>
###xml 184 192 184 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T </italic>
###xml 267 274 267 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 324 332 324 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T </italic>
###xml 518 525 518 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13T </italic>
###xml 558 564 558 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13 </italic>
###xml 568 576 568 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T </italic>
###xml 684 692 684 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T </italic>
###xml 1054 1061 1054 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T</italic>
###xml 1216 1222 1216 1222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13 </italic>
###xml 1408 1416 1408 1416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T </italic>
GHRLOS overlaps a putative SEC13 isoform, SEC13-T, in an antisense manner. (A) Diagrammatic representation of GHRLOS, SEC13, and a novel SEC13 isoform, named SEC13-tentative (SEC13T). SEC13-T contains a novel terminal exon 9, termed exon 9b, which overlaps exon 4 of GHRLOS in an antisense manner. In the figure, exon 9b of SEC13-T is dotted to indicate that its complete 3' end has not been verified. Exons are represented as boxes and introns as horizontal lines. The locations of the primers employed to verify the SEC13T variant are displayed as arrows. SEC13 and SEC13-T GenBank accession numbers are shown. (B) Ethidium bromide stained agarose gel showing the verification of a SEC13-T EST [GenBank:] transcription by RT-PCR in prostate (RWPE-1 and RWPE-2) and prostate cancer derived cell lines (DU-145, PC3, LNCaP). NTC = no template control (water). M= DNA Molecular Weight Marker VI (Roche). Primer locations are depicted in (A). A 231 PCR fragment was amplified and sequenced, confirming the EST. (C) RNA and amino acid sequence of exon 9b of SEC13-T. Additional downstream sequence corresponding to 18 in-frame codons and a stop codon is highlighted in green. (D) SEC13 and SEC13-T amino acid sequences. SEC13 encodes a 322 AA protein with six WD-40 repeats (also known as WD or beta-transducin repeats) are underlined. Amino acid sequence of SEC13 which is different to SEC13T is shown in blue. SEC13-T may encode a 372 AA protein: Its first 285 amino acids are identical to SEC13 and the normal C-terminal 37 amino acids have been replaced by 87 amino acids (shown in red) encoded by exon 9b.
###end p 34
###begin title 35
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
GHRLOS is expressed in many tissues and cell lines and the level of expression shows great variability
###end title 35
###begin p 36
###xml 39 46 39 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 172 179 172 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 379 386 379 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 463 470 463 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 687 694 687 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 733 740 733 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 761 763 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
RT-PCR analysis (with primers spanning GHRLOS terminal exons) and Northern blotting (which is only suitable for high copy number transcripts) demonstrated that the size of GHRLOS transcripts is highly variable, resulting in significant transcript heterogeneity. We, therefore, employed a quantitative, real-time RT-PCR approach in order to more precisely gauge the expression of GHRLOS in a range of tissues and cell lines. As the number of alternatively spliced GHRLOS transcripts makes it impossible to generate real-time RT-PCR primers that are unique to each splice variant (data not shown), a strand-specific quantitative RT-PCR assay with primers in exon 4 (which is common to all GHRLOS variants) was designed to detect total GHRLOS RNA expression (Fig. 7A).
###end p 36
###begin p 37
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 0 39 0 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Strand-specific <italic>GHRLOS </italic>real-time RT-PCR</bold>
###xml 99 106 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 236 242 236 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 261 268 261 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 517 520 517 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 645 652 645 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 717 724 717 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 974 981 974 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1088 1090 1088 1090 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 1118 1124 1118 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 677 682 <span type="species:ncbi:9606">human</span>
###xml 683 688 <span type="species:ncbi:9606">human</span>
###xml 738 743 <span type="species:ncbi:9606">human</span>
###xml 906 911 <span type="species:ncbi:9606">human</span>
Strand-specific GHRLOS real-time RT-PCR. (A) Strand-specific real-time RT-PCR approach to quantify GHRLOS expression. To select for RNA generated from the antisense strand, a linker sequence (LK) (not present in the genomic sequence of GHRLOS) is attached to a GHRLOS gene specific primer and employed in reverse transcription. The resulting cDNA is then combined in a real-time PCR, combining a gene-specific primer (GSP) and a primer containing the linker region from reverse transcription primer only. An internal TaqMan probe (depicted as a blue box) was employed to increase the specificity and sensitivity of the assay. (B) Relative total GHRLOS expression in a range of human human tissues. (C) Relative total GHRLOS expression in human cell lines (U-937 non-Hodgkin's lymphoma, SW1353 chondrosarcoma, CaCo-2 colorectal adenocarcinoma, SAOS-2 osteosarcoma, U-87 MG and U-251 MG glioblastoma, HEK293 human embryonic kidney and OVCAR-3 ovarian cancer). Calculations of GHRLOS expression levels were performed using the standard curve method (correlating the threshold cycle number (CT values) and copy numbers of GHRLOS), and normalised to the expression of 18S ribosomal RNA. Each bar presents the mean +/- standard deviation of duplicate reactions.
###end p 37
###begin p 38
###xml 19 26 19 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 223 230 223 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7B</xref>
###xml 405 413 405 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P &lt; 0.01</italic>
###xml 461 469 461 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P &lt; 0.01</italic>
###xml 572 580 572 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P &lt; 0.05</italic>
###xml 680 687 680 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 793 801 793 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P &gt; 0.05</italic>
###xml 76 81 <span type="species:ncbi:9606">human</span>
The level of total GHRLOS transcript expression varied greatly in different human tissues, with high levels in the thymus, testis, foetal brain, uterus, cerebellum, ovary, thyroid, and whole brain. Very low levels of total GHRLOS RNA expression were detected in the stomach, foetal liver and pancreas (Fig. 7B). In the thymus the level of expression was approximately 133 fold higher than in the stomach (P < 0.01) and 110-fold higher than in the foetal liver (P < 0.01). Furthermore, the level of expression in the adult liver was 9-fold higher than in the foetal liver (P < 0.05), indicating differential expression according to developmental stage in this tissue. The level of GHRLOS in the foetal brain was two-fold higher than the adult brain, but this was not statistically significant (P > 0.05).
###end p 38
###begin p 39
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7C</xref>
###xml 120 127 120 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 659 666 659 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 688 689 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 693 700 693 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 804 812 804 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P &lt; 0.05</italic>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7B</xref>
###xml 827 829 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7C</xref>
###xml 869 876 869 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 342 347 <span type="species:ncbi:9606">human</span>
Expression of GHRLOS in a number of continuous cell lines was also examined using real-time RT-PCR (Fig. 7C). Levels of GHRLOS expression in the U-937 (Non-Hodgkin's lymphoma) and SW1353 (chondrosarcoma) cell lines were similar to the cerebellum, uterus, foetal brain, testis and thymus. High levels of expression were observed in the HEK293 human embryonic kidney cell line and in the CaCo-2 (colon adenocarcinoma), SAOS-2 (osteosarcoma), U-87 MG and U251-MG (glioblastoma), OVCAR-3 (ovarian adenocarcinoma) and Hep G2 (hepatocarcinoma) cancer cell lines. It is interesting to note that multiple Hep G2 CAGE tags have been identified in the exon I region of GHRLOS (see [Additional File 4]). GHRLOS RNA appears to be significantly upregulated in the Hep G2 cell line compared to adult and foetal liver (P < 0.05) (Fig. 7B and 7C). This observation could indicate that GHRLOS may be a specific target in the development of liver and other cancers.
###end p 39
###begin title 40
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL</italic>
Comparison of total GHRLOS and total GHRL expression
###end title 40
###begin p 41
###xml 41 56 41 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL-GHRLOS cis</italic>
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 195 199 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL</italic>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 241 246 241 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 379 386 379 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 417 422 417 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 468 474 468 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 481 488 481 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 520 529 520 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P &lt; 0.001</italic>
###xml 546 553 546 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 581 586 581 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 687 692 687 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 720 727 720 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
We examined the expression levels of the GHRL-GHRLOS cis-natural antisense transcript (cis-NAT) pair via quantitative real-time RT-PCR assays detecting total transcription from the ghrelin gene (GHRL). As expected [31], the highest level of GHRL expression was found in the stomach (data not shown), followed by the testis and pancreas (Fig. 8). When comparing total ghrelin and GHRLOS RNA expression in the stomach, GHRL was expressed at 2300 fold higher levels than GHRLOS, with GHRLOS expression almost undetectable (P < 0.001). The levels of GHRLOS expression were higher than GHRL in the thymus, whole brain, the SW1353 chondrosarcoma cell line, uterus and prostate. However, total GHRL RNA levels were higher than GHRLOS in the pancreas and the OVCAR-3 ovarian cancer cell line.
###end p 41
###begin p 42
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 39 46 39 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 0 62 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Comparison of strand-specific <italic>GHRL </italic>and <italic>GHRLOS </italic>real-time RT-PCR</bold>
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 103 110 103 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 321 323 321 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 351 356 351 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 360 366 360 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 164 169 <span type="species:ncbi:9606">human</span>
Comparison of strand-specific GHRL and GHRLOS real-time RT-PCR. Relative total GHRL (sense, black) and GHRLOS (antisense, grey) RNA transcript expression levels in human tissues and cell lines. Calculations of RNA expression levels were performed using the standard curve method (correlating the threshold cycle number (CT values) and copy numbers of GHRL and GHRLOS) normalised to the expression of 18S ribosomal RNA. Each bar presents the mean +/- standard deviation of duplicate reactions.
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 28 35 28 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 246 253 246 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 379 380 379 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9</xref>
###xml 452 459 452 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 543 549 543 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2</italic>
###xml 669 675 669 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 755 760 755 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gnas </italic>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 748 754 <span type="species:ncbi:10090">murine</span>
Our study demonstrates that GHRLOS gives rise to long, extensively spliced, mRNA-like, 5' capped and 3' polyadenylated transcripts suggesting that they are genuine products of RNA polymerase II mediated transcription [32]. We have shown that the GHRLOS gene gives rise to transcripts 1.0 to 5.5 kb in size and has many broadly distributed transcription starts sites (TSSs) (Fig. 9). This includes several TSSs in exon 1, TSSs overlapping the 3' UTR of TATDN2 and evidence of transcription induced chimaeras employing TSSs in the first exon of TATDN2. The ghrelin locus, therefore, gives rise to many antisense transcripts that are currently annotated as a single gene, GHRLOS. A well-described example of such complex architecture is the imprinted murine Gnas locus, which gives rise to multiple coding and non-coding sense and antisense transcription units [33].
###end p 44
###begin p 45
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 0 38 0 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Structure of genes at the <italic>GHRLOS </italic>locus</bold>
###xml 63 70 63 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 89 93 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL</italic>
###xml 359 363 359 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL</italic>
###xml 394 401 394 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 509 516 509 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 57 62 <span type="species:ncbi:9606">human</span>
Structure of genes at the GHRLOS locus. Structure of the human GHRLOS (top) and ghrelin (GHRL) (bottom) genes. Exons are shown as boxes and introns as lines. Genes on the positive DNA strand are displayed above the double-lines, while genes on the negative DNA strand are shown below. Arrows indicate transcription start sites of GHRLOS transcripts. Ghrelin (GHRL) exons are shown in grey, and GHRLOS in black. A novel exon of a putative SEC13 variant, SEC13-T is shown as white boxes. The terminal exon 8 of TATDN2 is indicated by a dotted line.
###end p 45
###begin p 46
###xml 24 26 24 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 589 596 589 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 639 646 639 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 695 702 695 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 768 775 768 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 872 878 872 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2</italic>
###xml 987 989 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1053 1059 1053 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2</italic>
###xml 1077 1084 1077 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
First reported in 1987 [34] and originally thought to be a rarity, it has recently been established that promoters in 3' untranslated regions (3' UTRs) are not uncommon and may be independently transcribed and regulated from their upstream "host gene" [35]. The ENCODE (ENCyclopedia Of DNA Elements) consortium has recently demonstrated that two-thirds of the loci in their dataset contain new putative first exons, which frequently overlap upstream genes [36]. However, it is currently not known how promoters that overlap 3' UTRs are regulated and coordinated [37]. We have demonstrated GHRLOS transcription start sites in the 3' UTR of TATDN2 via RLM-RACE. The sequence upstream of exon I of GHRLOS contains no apparent TATA boxes (data not shown), indicating that GHRLOS has a broad type promoter, with many potential transcription start sites in the 2.1 kb 3' UTR of TATDN2. This may allow the transcription of numerous tissue-specific and developmental stage-specific transcripts [19]. In addition, multiple CAGE tags are present in the 3' UTR of TATDN2, indicating that GHRLOS transcripts initiate in this region.
###end p 46
###begin p 47
###xml 77 84 77 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 398 401 398 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 503 509 503 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans-</italic>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 644 658 644 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2-GHRLOS </italic>
###xml 779 783 779 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis </italic>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 793 807 793 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2-GHRLOS </italic>
###xml 1175 1177 1175 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1248 1255 1248 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 1371 1379 1371 1379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 1380 1382 1380 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1563 1570 1563 1570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 1677 1691 1677 1691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2-GHRLOS </italic>
###xml 2034 2036 2034 2036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 2271 2273 2271 2273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1371 1378 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Interestingly, we also report the joining of exons of the neighbouring genes TATDN2 and GHRLOS. Similar chimaeric transcripts (not caused by chromosomal translocation) have been reported in lower eukaryotes [38,39], but were until recently assumed to be relatively rare in mammals [20,40-43]. It is not known how chimaeric transcripts arise, but transcriptional read-through, followed by canonical cis-splicing is the most likely mechanism [40]. Alternatively, chimaeric transcripts could arise through trans-splicing, but the existence of this mechanism has not been well-established in mammals [44]. We, therefore, suggest that the chimaeric TATDN2-GHRLOS transcripts probably result from a single pre-mRNA, creating transcription-induced chimaeras (TICs) which are spliced in cis [40]. The TATDN2-GHRLOS TIC which was identified in the normal thymus harbours premature stop codons (PTCs) and this is likely to result in nonsense-mediated decay (NMD). NMD is an RNA surveillance mechanism (present in eukaryotes) which targets mRNA with premature stop codons that, if translated, encode truncated proteins with dominant-negative or deleterious gain-of function activities [21]. Whilst we are not aware of any studies of the translated product of TATDN2 (TatD DNase domain containing 2), TatD is a cytoplasmic protein that harbours magnesium-dependent DNase activity in E. coli [45]. Proteins with a TatD domain, therefore, belong to the large superfamily of metalloenzymes. This suggests that the chimaeric transcripts may play a role in auto-regulation of the TATDN2 protein product, which we hypothesise is likely to be a DNase associated with apoptosis. We speculate that TATDN2-GHRLOS chimaeras may be used to tightly regulate the programmed cell death of T-cells by downregulating the translation of the putative DNase TATDN2. Hillman and colleagues have termed this system of auto-regulation, where alternative splicing results in mRNA isoforms that are not translated, regulated unproductive splicing and translation (RUST) [46]. Interestingly, it has very recently been reported that transcripts of the tumour suppressor protein E-cadherin that result in non-sense mediated decay are upregulated in gastric cancer, suggesting that NMD may also promote disease [47].
###end p 47
###begin p 48
###xml 28 35 28 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL</italic>
###xml 80 81 80 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 133 140 133 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 210 216 210 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13 </italic>
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 589 596 589 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 613 619 613 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13 </italic>
###xml 645 652 645 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T</italic>
###xml 655 663 655 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T </italic>
###xml 894 902 894 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T </italic>
###xml 976 983 976 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1019 1024 1019 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 1028 1035 1028 1035 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T</italic>
###xml 1041 1048 1041 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
We previously reported that GHRLOS completely overlaps the ghrelin (GHRL) gene [8]. Here we also show that the 3' terminal exon 4 of GHRLOS is present on the opposite (antisense) strand to a novel, 3' terminal SEC13 exon (Fig. 8). SEC13 is a protein that forms a part of the coat protein complex II (COPII) [28]. COPII proteins are required for the trafficking of nascent proteins from the endoplasmic reticulum (ER) to the Golgi apparatus. It also plays a role in the selection and concentration of cargo proteins for transport [29]. SEC13 [28], therefore, has a core endocrine function. GHRLOS overlaps a novel SEC13 variant, SEC13-tentative (SEC13-T). SEC13-T may encode a 372 amino acid protein with a unique C-terminus. Future studies are required to confirm the presence of full-length transcripts and to elucidate the functional role of SEC13-T protein. We suggest that transcription of SEC13-T may have implications for COPII function in health and disease states. As GHRLOS overlaps the terminal exons of both GHRL and SEC13-T, the GHRLOS natural antisense transcripts may regulate one or both of these genes.
###end p 48
###begin title 49
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
GHRLOS, a candidate non-coding RNA
###end title 49
###begin p 50
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 394 404 394 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 448 459 448 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 907 909 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 910 912 910 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 919 929 919 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 952 959 952 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1047 1054 1047 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1131 1133 1131 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1134 1136 1134 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 586 590 <span type="species:ncbi:10090">mice</span>
###xml 596 602 <span type="species:ncbi:9606">humans</span>
Non-coding RNAs are frequently not conserved between species, suggesting that they are either biological noise (non-functional transcription), or that they have species specific-functions. Species-specific non-coding transcripts have been observed and there is strong evidence that non-coding transcripts are functionally significant [48-52]. Interestingly it has recently been observed, using in silico analysis, that even between closely related Drosophila species non-coding RNAs are not conserved [53]. While the number of protein coding genes in distant eukaryotes (such as worms, mice, and humans) is approximately equal, the relative amount of non-coding DNA increases in proportion to eukaryotic complexity [54,55]. Mattick and colleagues explain this paradox by hypothesising that non-coding RNAs have evolved to enable the emergence of organisms with increasingly complex higher levels functions [55,56]. Our in silico analysis suggests that GHRLOS exons show very low sequence conservation in vertebrate species. Furthermore, exon 4 of GHRLOS contains a transposable element, a feature observed in many non-coding RNAs [25-27].
###end p 50
###begin p 51
###xml 40 47 40 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 158 164 158 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 229 236 229 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 726 733 726 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 815 822 815 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 783 788 <span type="species:ncbi:10090">mouse</span>
Our bioinformatic studies indicate that GHRLOS does not encode a protein and, therefore, is a non-coding RNA. Taking into account the full-length sequence of GHRLOS, the length of the open reading frames is very short. Moreover, GHRLOS RNAs are numerous (due to extensive splicing), contain a large number of stop codons and there is little nucleotide and putative amino acid conservation between vertebrates, making it less likely that this gene encodes proteins. Although it has been suggested that many small peptides may be translated [57], the majority of small peptides are processed from larger precursor proteins, as is ghrelin itself which is processed from preproghrelin. Therefore, while it cannot be excluded that GHRLOS encodes short ORFs (that are not conserved in the mouse) it appears unlikely that GHRLOS encodes biologically active peptides.
###end p 51
###begin p 52
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 431 441 431 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 774 781 774 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 887 892 887 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 913 914 913 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 969 976 969 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1207 1214 1207 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1317 1324 1317 1324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1469 1471 1469 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 1472 1474 1472 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 1702 1709 1702 1709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 284 290 <span type="species:ncbi:9606">humans</span>
###xml 295 299 <span type="species:ncbi:10090">mice</span>
We examined the GHRLOS expression profile to strengthen the hypothesis that it is a candidate non-coding RNA. It has been demonstrated that mammalian long non-coding RNAs are expressed in a tissue-specific manner, indicating that they are biologically significant [50,58-61]. In both humans and mice, the major tissues of non-coding expression are the complex organs; the brain, testis, and thymus [50,61]. This also holds true in Drosophila, where the majority of the candidate non-coding RNAs are expressed in the central nervous system [53]. Indeed, non-coding RNAs are emerging as important regulators of complex systems, such as the central nervous system (brain) and intricate processes, including spermatogenesis in the testis [62-65]. We demonstrated high levels of GHRLOS in the thymus, brain, testis, uterus, ovary and thymus, while the expression levels in the stomach, where GHRL is highly expressed [1], were almost undetectable. Our data demonstrate that GHRLOS is predominantly expressed in a limited number of tissues and cell types, suggesting that these transcripts have physiological functions in distinct cell types and tissues. Moreover, real-time RT-PCR showed extremely low levels of GHRLOS in the foetal and adult liver and high levels in the Hep G2 hepatocarcinoma cell line, suggesting that GHRLOS expression may be altered in liver cancer. Indeed, it has recently been reported that non-coding RNA expression is frequently altered in cancer [58,66]. This indicates that non-coding RNAs may have specific functions in normal cells. Much like protein-coding transcripts, ncRNAs may act as tumour suppressors, or be upregulated in cancer and act as oncogenes. An examination of GHRLOS expression in cancer would, therefore, be of great interest.
###end p 52
###begin p 53
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 111 118 111 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 175 182 175 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FMR1 </italic>
###xml 451 454 451 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 459 466 459 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ASFMR1 </italic>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 499 504 499 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FMR4 </italic>
###xml 528 533 528 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FMR1 </italic>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
Here we have characterised the structure and organisation of GHRLOS, a ghrelin antisense gene, suggesting that GHRLOS has multiple first exons. Therefore, it is possible that GHRLOS could be a part of very large, continuous ncRNA species in the 3p25 chromosomal region and beyond. In the absence of hallmarks, such as large open reading frames, mapping complex non-coding RNA genes remains a complex task. For example, two RNAs in the FMR1 locus, the cis-NAT ASFMR1 [67] and the non-coding RNA gene FMR4 (found just upstream of FMR1 [51]) may be one continuous RNA isoform [51].
###end p 53
###begin title 54
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
What is the function of GHRLOS?
###end title 54
###begin p 55
###xml 415 417 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 514 518 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis </italic>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 574 580 574 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans </italic>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 811 813 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 858 865 858 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 936 938 936 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
###xml 943 950 943 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1018 1020 1018 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 1042 1044 1042 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B80">80</xref>
###xml 1058 1060 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B81">81</xref>
###xml 1109 1111 1109 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B82">82</xref>
###xml 1112 1114 1112 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B83">83</xref>
###xml 753 758 <span type="species:ncbi:9606">human</span>
It is currently difficult and costly to determine the mechanism of function of long non-coding RNAs. The roles of non-coding RNAs are likely to be diverse, and there is strong evidence that they play a role in regulating important pathways. Many ncRNAs are expressed during development, neural differentiation, during macrophage activation and in cancer, indicating that they have key functions in these processes [12,63,68]. Non-coding RNAs have been found to play a role in the silencing of overlapping genes in cis [69], in the silencing of distant chromosome regions in trans [70], in nuclear trafficking [71], apoptosis [51,72], promoter repression [73], and can act as tumour suppressors [74]. Moreover, ncRNAs are emerging as markers for complex human disease, including lung cancer [75], heart disease [76], and a range of other pathologies [68,77]. GHRLOS may also serve as a host gene for snoRNA (small nucleolar RNAs) genes [78] or GHRLOS RNA transcripts may be precursors for short RNAs, such as micoRNAs [77], endogenous siRNAs [79,80], piRNAs [81] and other novel, short non-coding RNA species [82,83].
###end p 55
###begin p 56
###xml 358 359 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B84">84</xref>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
Although the understanding of natural antisense transcripts (NATs) remains in its infancy, they have been associated with a range of regulatory mechanisms that are not necessarily mutually exclusive. This includes transcriptional interference, RNA masking and dsRNA mediated gene-silencing via direct interaction between the sense and antisense transcripts [9,84,85].
###end p 56
###begin p 57
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 76 83 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 195 202 195 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B86">86</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B87">87</xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B88">88</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B89">89</xref>
###xml 650 653 650 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B90">90</xref>
###xml 948 954 948 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
While it is difficult to predict GHRLOS function, the fact that all spliced GHRLOS variants share exon 1, which overlaps the 3' untranslated exon 4 of GHRL is striking. Our findings suggest that GHRLOS functions as a non-coding RNA. There are a few examples that suggest that antisense transcripts are important in the regulation of endocrine hormone receptors, including a thyroid hormone receptor [86,87], and the luteinising hormone/choriogonadotropin receptor [88] gene and in the regulation of growth factors [89]. Interestingly, it has been recently suggested that the invertebrate (insect) polypeptide hormone allatostatin may be regulated by cis-NATs [90]. To date, however the physiological and pathophysiological roles of natural sense/antisense pairs have not been elucidated for any vertebrate endocrine hormone. Further studies are necessary to reveal the function and molecular mechanisms regulating the candidate non-coding RNA gene GHRLOS.
###end p 57
###begin title 58
Conclusion
###end title 58
###begin p 59
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 122 129 122 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 370 377 370 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 433 438 433 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 450 456 450 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13 </italic>
###xml 505 512 505 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 575 589 575 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2-GHRLOS </italic>
###xml 737 744 737 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1046 1053 1046 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
In the present study, we have characterised GHRLOS, which gives rise to endogenous ghrelin natural antisense transcripts. GHRLOS exhibits features which are common to many non-coding RNA genes, including extensive splicing, lack of significant and conserved open reading frames, differential expression and lack of conservation in vertebrates. Our data also reveal that GHRLOS contains multiple first exons and that it overlaps both GHRL and a novel SEC13 exon in the antisense direction, suggesting that GHRLOS may have a role in regulating these genes. Moreover, we report TATDN2-GHRLOS chimaeras that may function to regulate the translation of the putative DNase TATDN2. Additional studies are underway to elucidate the functions of GHRLOS and to investigate, in particular, its overlapping genomic arrangement with the ghrelin gene. These studies may provide a new, physiologically relevant model system for investigating the roles of antisense gene and non-coding RNA regulation and the mechanisms involved, as well as establishing whether GHRLOS RNAs may be useful markers for diagnosis and prognosis of complex disease.
###end p 59
###begin title 60
Methods
###end title 60
###begin title 61
Bioinformatics
###end title 61
###begin p 62
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B91">91</xref>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B92">92</xref>
###xml 497 504 497 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 511 518 511 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 138 143 <span type="species:ncbi:9606">Human</span>
###xml 157 164 <span type="species:ncbi:9031">chicken</span>
###xml 226 231 <span type="species:ncbi:10090">mouse</span>
###xml 244 247 <span type="species:ncbi:10116">rat</span>
###xml 260 263 <span type="species:ncbi:9615">dog</span>
###xml 280 294 <span type="species:ncbi:9544">rhesus macaque</span>
###xml 315 325 <span type="species:ncbi:9598">chimpanzee</span>
Multiple sequence alignments were generated using the MUltiple sequence Local AligNment and conservation visualization tool (Mulan) [91]. Human [UCSC hg18], chicken [UCSC galGal3], frog [UCSC xenTro2], opossum [UCSC monDom4], mouse [UCSC mm9], rat [UCSC rn4], dog [UCSC canFam2], rhesus macaque [UCSC rheMac2], and chimpanzee [UCSC PanTro2] genomic sequences were obtained via the Evolutionary Conserved Regions (ECRs) Browser [92] and forwarded to Mulan to generate a full local alignment of the GHRLOS locus. GHRLOS was annotated based on the exons sequenced in this study.
###end p 62
###begin p 63
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B93">93</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B94">94</xref>
###xml 100 105 <span type="species:ncbi:9606">Human</span>
To identify putative antisense exons and transcripts, we examined the publicly available Affymetrix Human Exon 1.0 ST Array tissue panel dataset consisting of 11 tissues (breast, cerebellum, heart, kidney, liver, muscle, pancreas, prostate, spleen, testes, and thyroid) using the Affymetrix All Exon track in the UCSC Genome Browser [93] and the Integrated Genome Browser (IGB) from Affymetrix [94].
###end p 63
###begin p 64
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B95">95</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B96">96</xref>
To locate transcription start sites in the putative first exons of GHRLOS, CAGE (Cap Analysis of Gene Expression) tags (deposited by the RIKEN consortium and its collaborators) were obtained via the Genome Network Platform Viewer [95]. We then recovered the RNA library information for each CAGE tag starting site. Briefly, each CAGE tag was individually queried against the 1.4 GB CAGE tag sequencing file, (release date 13.11.2006) available on the Genome Network Platform website using the UNIX grep command [96].
###end p 64
###begin p 65
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B97">97</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B98">98</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B99">99</xref>
###xml 327 330 327 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B100">100</xref>
###xml 331 334 331 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B101">101</xref>
###xml 378 385 378 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 497 500 497 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B102">102</xref>
###xml 168 173 <span type="species:ncbi:9606">human</span>
The exon-intron-structure of ESTs and mRNA entries identified from BLAST searches, as well as sequenced PCR amplicons obtained in this study, were analysed against the human genome (NCBI release 35) using GMAP [14]. Presence of open reading frames was analysed by NCBI ORF Finder [97], Fickett's TestCode [98,99] and ESTScan2 [100,101]. The presence of transposable elements in GHRLOS sequence was examined using CENSOR v4.2.8 [22]. Protein domain analysis was performed using the SMART database [102].
###end p 65
###begin title 66
Cell culture and RNA extraction
###end title 66
###begin p 67
###xml 800 802 800 802 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 367 372 <span type="species:ncbi:9606">human</span>
The following cell lines (originally obtained from the American Type Culture Collection/ATCC, Rockville, MD unless specified) were cultured in their recommended media: Prostate and/or prostate cancer derived cell lines DU145 (ATCC HTB-81), RWPE-1 (ATCC CRL-11609), RWPE-2 (ATCC CRL-11610), LNCaP (ATCC CRL-1740), 22Rv1 (ATCC CRL-2505) and PC3 (ATCC CRL-1435), HEK293 human embryonic kidney (ATCC CRL-1573), SAOS-2 osteosarcoma (ATCC HTB-85), Hep G2 hepatocarcinoma (ATCC HB-8065), U-87 MG and U-251 MG glioblastoma (ATCC HTB-14 and JCRB Cell Bank # IFO50288, respectively), CaCo-2 colorectal adenocarcinoma (ATCC HTB-37), SW1353 chondrosarcoma (ATCC HTB-94), and OVCAR-3 ovarian cancer (ATCC HTB-161). All cells were grown in T80 or T175 flasks (Nagle Nunc International, Roskilde, Denmark) in 95% CO2 in a Sanyo incubator at 37degreesC. Total RNA was harvested from cultured cells at 70% confluence using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.
###end p 67
###begin title 68
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human RNA samples
###end title 68
###begin p 69
###xml 299 304 <span type="species:ncbi:9606">Human</span>
Tissue Total RNA was obtained from the stomach, prostate (FirstChoice, Ambion, Austin, TX), foetal liver, adrenal gland, liver, trachea, salivary gland, spinal cord, skeletal muscle, lung, placenta, bone marrow, kidney, heart, whole brain, thyroid, cerebellum, uterus, foetal brain, testis, thymus (Human total RNA Master Panel II, Clontech, Mountain View, CA) and pancreas (Clontech).
###end p 69
###begin title 70
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
5' and 3' RACE mapping of GHRLOS transcripts
###end title 70
###begin p 71
###xml 301 302 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 500 501 499 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 583 587 581 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 131 136 <span type="species:ncbi:9606">human</span>
To further characterise the 5' end of the putative ghrelin antisense RNAs, 5' RACE was undertaken using FirstChoice RLM-RACE-Ready human stomach cDNA (Ambion) according to the manufacturer's instructions. The first round PCR was performed with an adapter-specific sense primer (5'adapter-out-F, Table 1) and an exon 2-specific antisense primer (5'OS-out-R in Table 1). PCR product (1 mul) was used in a secondary, nested PCR with a gene specific primer in exon 2 (5'adapter-in-F and 5'OS-in-R, Table 1). PCRs were performed in a total reaction volume of 50 mul using 1 U of Platinum Taq Polymerase High Fidelity (Invitrogen) according to the manufacturer's instructions.
###end p 71
###begin p 72
Designations and sequences of oligonucleotides
###end p 72
###begin p 73
###xml 473 478 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 481 488 481 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 624 629 624 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 633 640 633 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
T7 promoter sequence in PCR primers is underlined. Linker sequence (LK) in the primer GHRLOS-Real-RT-LK and GHRL-Real-RT-LK is shown in bold. In primer 3' -RACE-adapter V denotes an A/G/C residue and N denotes A/G/C. Lowercase letters in primer Pthioate-hex denotes phosphothioate linkages. An uppercase P in primer Phospho-dT indicates that the synthetic oligonucleotide was 5' phosphorylated. Annealing temperatures (Ta) of oligonucleotides employed in PCR is shown. The GHRL or GHRLOS exon location of nucleotides are listed, while oligonucleotides spanning synthetic sequences (adapters and linkers) or genes other than GHRL and GHRLOS are denoted as N/A.
###end p 73
###begin p 74
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 252 253 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 408 414 406 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 501 502 499 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 612 613 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 757 758 755 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 864 876 862 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pCR-XL-TOPO </italic>
###xml 892 904 890 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pGEM-T Easy </italic>
###xml 20 25 <span type="species:ncbi:9606">human</span>
For GHRLOS 3' RACE, human stomach and PC3 prostate cancer cell line total RNA was reverse transcribed using Transcriptor reverse transcriptase (Roche Applied Science Applied Science, Penzberg, Germany) and 10 muM adapter primer (3'-RACE-adapter, Table 1) from the FirstChoice RLM-RACE Kit (Ambion). 3' RACE was performed with 2 mul of this cDNA. Two 3' RACE reactions were performed - one combined an exon 4 GHRLOS-specific forward primer and an adapter-specific reverse primer (3'4F and 3'2OR, Table 1), and the other used an adapter-specific reverse primer and an exon 2-specific forward primer 3'2OR/F, Table 1). PCR products were then diluted and used in a secondary, nested PCR with a gene-specific forward and a reverse adapter primer (3'2IF/R, Table 1). PCR products were purified using a High Pure PCR purification kit (Roche Applied Science), cloned into pCR-XL-TOPO (Invitrogen) or pGEM-T Easy (Promega, Madison, WI), transformed into DH5alpha chemical competent cells (Invitrogen) and sequenced at the Australian Genome Research Facility (AGRF, Brisbane, Australia) using BigDye III (Applied Biosystems, AB, Foster City, CA).
###end p 74
###begin title 75
###xml 17 24 17 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
Determination of GHRLOS transcription start and polyadenylation sites by Rolling Circle Amplification Rapid Amplification of cDNA Ends (RCA-RACE)
###end title 75
###begin p 76
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 148 151 148 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B103">103</xref>
###xml 473 474 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1104 1105 1096 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1254 1258 1240 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 1653 1654 1637 1638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1881 1882 1852 1853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1990 2002 1960 1972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pCR-XL-TOPO </italic>
To simultaneously obtain the 5' and 3' ends of GHRLOS transcripts, we employed Rolling Circle Amplification-RACE (Rapid Amplification of cDNA Ends [103], an improved inverse PCR approach. Briefly, 3 mug stomach, prostate, RWPE-1 cell line and PC3 prostate cancer cell line total RNA were reverse transcribed using 10 U of Transcriptor reverse transcriptase (Roche Applied Science) and 100 muM HPLC-purified 5'-end phosphorylated oligo d(T)-adapter primer (Phospo-dT, Table 1) (Proligo, Boulder, CO) according to the manufacturer's instructions. The single-stranded cDNA was purified using a High Pure PCR purification kit (Roche Applied Science) and eluted in 50 mul elution buffer (10 mM Tris-HCl, pH 8.5). Next, 25 mul purified linear cDNA was circularised using 100 U of CircLigase (EPICENTRE Biotechnologies, Madison, WI) and purified as before. After self-ligation, 15 mul circular cDNA was added to a rolling circle amplification reaction with 10 U of phi 29 DNA polymerase (NEB) and 10 muM HPLC-purified random hexamer primers with two phosphothioate linkages on their 3'ends (Pthioate-hex, Table 1) (Proligo). Following a 21 h incubation at 30degreesC in a waterbath, RCA-products were subjected to two rounds of inverse PCR with 1 U of Platinum Taq HIFI polymerase (Invitrogen), as per manufacturer's instructions. PCRs were performed in a reaction volume of 50 mul using a PTC-200 thermocycler (MJ Research, Waltham, MA). For the first round amplification, the RCA reaction was diluted 1/100 in water, and 1 mul used in an outer PCR with a forward primer at the start of exon 4 and a reverse primer in exon I (IPCR-out-F and IPCR-ALL-R, Table 1). After 35 cycles at a 60degreesC annealing temperature, the outer PCR product was diluted 100 times in water and 1 mul was used in a hemi-nested PCR of 20 cycles, with annealing at 60degreesC (IPCR-in-F and IPCR-ALL-R, Table 1). Amplification products were eluted from agarose gels in 50 mul water overnight, reamplified, cloned into pCR-XL-TOPO (Invitrogen), transformed into One Shot MAX Efficiency DH5alpha-T1R chemically competent cells (Invitrogen) and sequenced at the Australian Genome Research Facility (AGRF, Brisbane, Australia).
###end p 76
###begin title 77
Northern blot hybridisation
###end title 77
###begin p 78
###xml 56 63 56 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 137 142 137 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SalI </italic>
###xml 401 403 401 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 508 511 508 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B103">103</xref>
Initially, a cRNA probe spanning exon I, II, 1 and 2 of GHRLOS was employed. Briefly, a 5' RACE clone in pGEM-T Easy was linearised with SalI restriction enzyme and a cRNA probe was synthesised using T7 RNA polymerase and a digoxigenin (DIG) RNA labelling kit (Roche Applied Science). Probe concentration was estimated by dot blot comparison with digoxigenin-labelled standards. 500 ng stomach poly(A)+ RNA (FirstChoice, Ambion) was separated on a 1.2% formaldehyde gel and blotted, as described previously [103]. Samples were electrophoresed with 50 ng RNA Molecular Weight Marker II (Roche Applied Science). The blot was hybridised to 50 ng/mL DIG-labelled cRNA probe overnight. Prehybridisation and hybridisation was performed with DIG-Easy Hyb (Roche Applied Science) at 65degreesC. The membranes were washed twice for 5 min at room temperature with 1 x Saline-Sodium Citrate (SSC), 0.1% sodium dodecyl sulfate (SDS) and then washed three times for 10 min at 65degreesC with 0.1 x SSC, 0.1% SDS. The membrane was then reacted with an alkaline phosphatase (AP)-conjugated anti-DIG antibody (Roche Applied Science). AP activity was detected using a chemiluminescence method using CDP-Star (Roche Applied Science).
###end p 78
###begin p 79
###xml 72 79 72 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 194 197 194 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B104">104</xref>
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 444 446 444 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 122 127 <span type="species:ncbi:9606">human</span>
###xml 458 463 <span type="species:ncbi:9606">human</span>
A second cRNA probe, which spanned exon 1 (which is common to all known GHRLOS mRNA isoforms) was synthesised from 100 ng human stomach genomic DNA (BioChain, Hayward, CA) using the PCR method [104] (Ex1-cRNA-F/R, Table 1). The PCR product was purified using a High Pure PCR Product Purification Kit (Roche Applied Science) and the DIG-labelled cRNA probe synthesised and quantified as detailed above. A multi-tissue membrane containing poly(A)+ RNA from 12 human tissues (brain, duodenum, oesophagus, pancreas, PBL/leukocytes, prostate, salivary gland, testis, thymus, thyroid, urinary bladder and uterus) was purchased from OriGene (Rockville, MD). Prehybridisation and hybridisation were performed as described above, except that ULTRAhyb Ultrasensitive Hybridization Buffer (Ambion) was used instead of DIG-Easy Hyb (Roche Applied Science). Equivalent loading between tissues on the blot was determined by rehybridising with 20 ng/mL DIG-labelled beta-actin cRNA probe (Roche Applied Science).
###end p 79
###begin title 80
###xml 35 42 35 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
Isolation of alternatively spliced GHRLOS mRNAs via non-quantitative RT-PCR
###end title 80
###begin p 81
###xml 40 47 40 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 200 207 200 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 499 500 497 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
For non-quantitative RT-PCR analysis of GHRLOS splicing, RT-PCRs were performed with a forward primer in a region common to the 5' terminal exon Ia/b and a reverse primer in the 3' terminal exon 4 of GHRLOS (Ito4-F/R, Table 1). cDNA was synthesised in a final volume of 20 mul from 3 mug total RNA from tissues and cell lines using 10 U of Transcriptor reverse transcriptase (Roche Applied Science), 20 U of RNasin Plus RNase Inhibitor (Promega) and a 3' RACE adapter primer (3'-RACE-adapter, Table 1) at 55degreesC according to the manufacturer's instructions. PCR amplicons from the stomach, prostate, foetal brain, heart, thymus, testis, and pancreas were purified, sub-cloned and sequenced as described above.
###end p 81
###begin title 82
###xml 47 61 47 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2-GHRLOS </italic>
Long-range RT-PCR to detect putative chimaeric TATDN2-GHRLOS transcripts
###end title 82
###begin p 83
###xml 93 100 93 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 154 161 154 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 223 227 223 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
To detect long, chimaeric transcripts, we employed RT-PCR with a forward primer in exon 2 of TATDN2 (ChiOut-F, Table 1) and a reverse primer in exon 1 of GHRLOS (ChiOut-R, Table 1). PCR was carried out with 1 U of Platinum Taq HIFI polymerase (Invitrogen) as per manufacturer's instructions, extending at 68degreesC for 2.5 minutes per cycle. cDNA was synthesised as above in a final volume of 20 mul from 2 mug total RNA, from the Hep G2 hepatocarcinoma cell line, CaCo-2 colorectal adenocarcinoma cell line, OVCAR-3 ovarian cancer cell line, and from a range of normal tissues (testis, prostate, pancreas, thymus, and foetal brain). RT-PCR products were sub-cloned and sequenced as described above.
###end p 83
###begin title 84
CAGE-aided cDNA primer walking
###end title 84
###begin p 85
###xml 96 102 96 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 259 266 259 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 357 364 357 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 404 405 404 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 702 705 700 703 <sub xmlns:xlink="http://www.w3.org/1999/xlink">18 </sub>
###xml 982 983 980 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1066 1070 1063 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 1277 1289 1274 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pCR-XL-TOPO </italic>
To determine if the identified upstream CAGE tag starting sites transcribe exons that belong to GHRLOS, we employed RT-PCR using a forward primer designed to the region immediately after a CAGE cluster in the ~2 kb 3' untranslated region of the adjacent gene TATDN2 (TSS ID T03F009D1927) and a reverse primer in exon 1, an exon which is common to all known GHRLOS variants (F_CAGE and R_CAGEout in Table 1, respectively). cDNA was synthesised in a final volume of 20 mul from 2 mug total RNA, from the Hep G2 hepatocarcinoma cell line and the thymus and foetal brain, using 10 units Transcriptor reverse transcriptase (Roche Applied Science), 20 U of RNasin Plus RNase Inhibitor (Promega) and oligo(dT)18 primers (Proligo) according to the manufacturer's instructions. The cDNAs were subjected to 35 cycles of PCR with a two-minute extension time per cycle, and then diluted 1/100 in water and subjected to a hemi-nested 30-cycle PCR with a nested primer in exon 1 (R_CAGEin, Table 1). PCRs were performed in a total reaction volume of 50 mul using 10 U of Platinum Taq Polymerase High Fidelity (Invitrogen) according to the manufacturer's instructions. Entire PCR products were purified using the High Pure PCR Product Purification Kit (Roche Applied Science), subcloned into pCR-XL-TOPO (Invitrogen) and transformed into One Shot MAX Efficiency DH5alpha-T1R chemical competent cells (Invitrogen). Insert-positive, purified clones were sequenced by the Australian Genome Research Facility (AGRF, Brisbane, Australia) using the AB PRISM BigDye Terminator Cycle Sequencing Kit v3.1 protocol (AB).
###end p 85
###begin title 86
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13 </italic>
Identification of novel SEC13 exon
###end title 86
###begin p 87
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13 </italic>
###xml 214 220 214 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13 </italic>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
To verify the presence of a novel SEC13 exon identified in a brain tumour EST [GenBank:], cDNAs reverse transcribed with an oligo(dT) primer (as described above) were challenged by RT-PCR with primers in exon 8 of SEC13 and a reverse primer in the novel exon (231-F/R, Table 1, respectively).
###end p 87
###begin title 88
Strand-specific, quantitative real-time RT-PCR
###end title 88
###begin p 89
###xml 57 60 57 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B105">105</xref>
###xml 61 64 61 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B107">107</xref>
###xml 69 76 69 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 184 187 184 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B107">107</xref>
###xml 236 242 236 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 566 572 559 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 594 595 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 635 636 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 655 660 648 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 830 831 823 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 906 907 899 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 958 959 951 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 993 1000 986 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 1004 1009 997 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 1084 1085 1077 1078 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T</sub>
###xml 1152 1153 1145 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1156 1160 1149 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">18S </italic>
###xml 1220 1226 1213 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 1227 1230 1220 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B107">107</xref>
###xml 1233 1237 1226 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">18S </italic>
###xml 319 322 <span type="species:ncbi:11866?0.5863095238095238|species:ncbi:12321?0.21726190476190477">AMV</span>
To allow strand-specific and RNA-specific amplification [105-107] of GHRLOS transcripts, reverse transcription was performed using a gene-specific primer in exon 4 with a linker (LK) [107] sequence attached to the 5' end of the primer (GHRLOS-Real-RT-LK, Table 1). cDNA was generated from 1 mug total RNA using 40 U of AMV reverse transcriptase (Roche Applied Science) at 42degreesC, according to the manufacturer's instructions. The strand-specific, real-time RT-PCR was performed with an exon 4 specific forward primer, a reverse primer with the LK sequence only (GHRLOS-Real-F and LK, Table 1) and a TaqMan probe (Ex4-TaqMan, Table 1). To detect sense GHRL transcripts, we employed a strand-specific RT-PCR approach, with a reverse transcription primer spanning the 3' terminal exon 4 of the ghrelin gene (GHRLex4_RT_LK, Table 1) followed by PCR with an exon 4 specific forward primer (GHRLex4_F, Table 1) and a linker-specific reverse primer. (LK, Table 1). The relative quantification of GHRLOS and GHRL transcripts was estimated by direct normalisation to the threshold cycle (CT) of the housekeeping gene, 18S ribosomal RNA (18S-Real-F/R, Table 1). 18S PCRs were used to normalise real-time data. As reported for GAPDH [107], 18S RNAs self-primes efficiently in reverse transcription reactions without the addition of random or gene-specific primers. All primers were designed using the Primer Express version 2.0 software (AB).
###end p 89
###begin p 90
###xml 125 131 124 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
###xml 139 144 138 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
PCRs were performed in a total reaction volume of 20 mul using Platinum Quantitative PCR SuperMix-UDG w/ROX (Invitrogen) for GHRLOS, while GHRL and the housekeeping gene 18S ribosomal RNA were amplified using 2 x SYBR green master mix (AB). Controls included the use of cDNA, which was reverse transcribed using random hexamers as primers, as well as the reverse transcription of RNA in the absence of primer. Real-time RT-PCR was performed using the AB 7000 sequence detection system (AB) and data analysed using the absolute standard curve method (User Bulletin #2, AB) to determine expression levels in a range of tissues and cell lines. Briefly, we calculated values from duplicate reactions for each sample from standards, which were constructed from PCR products. Statistical significance was determined using the Student's t-test and, where applicable, one-way analysis of variance (ANOVA) with Tukey post-hoc analysis. P-values of < 0.05 were considered to be statistically significant. Data are represented as mean +/- standard deviation (S.D.).
###end p 90
###begin title 91
Authors' contributions
###end title 91
###begin p 92
IS conceived and designed the study and carried out all experiments except quantitative real-time RT-PCR. SLC carried out real-time RT-PCR and the resulting statistical analyses. ACH and LKC participated in its design and coordination. All authors participated in interpreting the data, wrote, read and approved the final manuscript).
###end p 92
###begin title 93
Supplementary Material
###end title 93
###begin title 94
Additional file 1
###end title 94
###begin p 95
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 55 62 55 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 729 736 725 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
Overview of GHRLOS exon 1. This is a TIFF file showing GHRLOS transcription start sites and exon 1 sequence. Exon 1 and exons I, II and III, all of which splice into the 106 bp exon 1, are depicted as black boxes. Exons with transcription start sites are indicated by arrows in the direction of transcription. The sequence of the 106 bp exon 1, which splices into upstream exons, is shaded in grey. Transcription start sites in exon 1, previously determined via 5' RACE (Delta) and CAGE (Cap Analysis of Gene Expression) (*), are indicated, and the exact transcription start site nucleotides are underlined and in bold. For comparison, the sequence of the reference (sense) exon 4 of the ghrelin gene [GenBank:] is shown in red. GHRLOS exon 1 sequence is shown in upper case, while intron sequence is shown in lower case.
###end p 95
###begin p 96
Click here for file
###end p 96
###begin title 97
Additional file 2
###end title 97
###begin p 98
###xml 56 63 56 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 264 269 <span type="species:ncbi:9606">human</span>
Ethidium bromide stained agarose gel electrophoresis of GHRLOS exon I a/b to 4 non-quantitative RT-PCR amplicons from cultured cells and normal prostate and stomach tissue. This is a TIFF file showing the expression profile of exon I a/b to 4 amplicons in various human tissues and cell lines, indicating a complex splice pattern. M = MassRuler Express DNA ladder (Fermentas, Burlington, Canada).
###end p 98
###begin p 99
Click here for file
###end p 99
###begin title 100
Additional file 3
###end title 100
###begin p 101
###xml 24 31 24 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 80 86 80 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS</italic>
Compilation of exons of GHRLOS transcripts. This is a PDF file listing exons of GHRLOS. Exon and intron sizes (bp) are indicated. Experimental evidence from this study and/or external references for each exon are shown.
###end p 101
###begin p 102
Click here for file
###end p 102
###begin title 103
Additional file 4
###end title 103
###begin p 104
###xml 95 101 95 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2</italic>
###xml 191 198 191 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 221 228 221 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 407 414 407 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 717 724 717 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
###xml 796 803 796 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 864 871 864 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATDN2 </italic>
Overview of CAGE-aided primer walking amplicons and CAGE tags in the 3' untranslated exon 8 of TATDN2. This is a PDF file showing (A) The expression pattern of transcripts spanning exon 8 of TATDN2 (orange) and exon 1 of GHRLOS (blue) revealed via cDNA primer walking (exon shown as boxes, introns as lines, and sizes in bp indicated above each exon). (B) CAGE tags present in the 3' untranslated region of TATDN2 (H51BA34H0302-testis; H22BA47L0809-Hep G2 hepatocarcinoma; H21BB07A0112-Hep G2; H52BA49L1810-adrenal gland; H04BB25B1106-cerebrum; H63BA79F2401-heart; H59BA94L1109-SK-N-AS neuroblastoma cell line; H08BA37K2001-kidney malignancy; H21BA90I0206-HepG2 hepatocellular liver carcinoma; H62BB07A0901-SK-N-AS). TATDN2 exon sequence is shown in beige, intron sequence in lowercase and grey, GHRLOS sequence deduced from cDNA primer walking in orange, and the TATDN2 polyadenylation signal (AATAAA) is shown in red.
###end p 104
###begin p 105
Click here for file
###end p 105
###begin title 106
Additional file 5
###end title 106
###begin p 107
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 133 140 133 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 37 40 <span type="species:ncbi:9615">dog</span>
###xml 110 115 <span type="species:ncbi:9606">human</span>
###xml 129 132 <span type="species:ncbi:9615">dog</span>
Comparison of human (h) and putative dog GHRLOS exon sequences. This is a JPEG file showing the comparison of human and putative dog GHRLOS exon sequences. The alignments were generated by the ClustalW program and drawn by BOXSHADE . Black shading indicates conserved nucleotides. (A) Exon II (B) Exon 2 (C) Exon 3.
###end p 107
###begin p 108
Click here for file
###end p 108
###begin title 109
Additional file 6
###end title 109
###begin p 110
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 89 96 89 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRLOS </italic>
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GHRL </italic>
###xml 165 173 165 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC13-T </italic>
Overview of GHRLOS exon 4 and overlapping exons. This is a TIFF file with an overview of GHRLOS exon 4 (highlighted in grey) showing the overlap with sense GHRL and SEC13-T exons (boxed). GT/AG intron splice sites are underlined. The exon 4 polyA signal is depicted in orange font. A stretch of poly(A) in the genomic sequence (exon 4) resulting of frequent oligo(dT) mispriming during cDNA synthesis is highlighted in pink.
###end p 110
###begin p 111
Click here for file
###end p 111
###begin title 112
Acknowledgements
###end title 112
###begin p 113
This work was supported by grants from the Cancer Council Queensland (to LKC and ACH), the Faculty of Science, Queensland University of Technology and a QUT International Doctoral Scholarship (to IS). We thank Dr Yaowu He (IHBI, Kelvin Grove, Australia) for the U-937, U-87 MG and U-251 MG cell lines; Carina Walpole (IHBI) for the OVCAR-3 cell line; and Dr Penny Jeffery (Mater Medical Research Institute, South Brisbane, Australia) for the CaCo-2 colorectal adenocarcinoma cell line.
###end p 113
###begin article-title 114
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
###end article-title 114
###begin article-title 115
###xml 77 81 <span type="species:ncbi:10090">mice</span>
Ghrelin differentially affects hepatic and peripheral insulin sensitivity in mice
###end article-title 115
###begin article-title 116
Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a
###end article-title 116
###begin article-title 117
Acylated ghrelin stimulates food intake in the fed and fasted states but desacylated ghrelin has no effect
###end article-title 117
###begin article-title 118
###xml 68 74 <span type="species:ncbi:9606">humans</span>
Influence of ghrelin on interdigestive gastrointestinal motility in humans
###end article-title 118
###begin article-title 119
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking ghrelin receptors resist the development of diet-induced obesity
###end article-title 119
###begin article-title 120
The physiology and potential clinical applications of ghrelin, a novel peptide hormone
###end article-title 120
###begin article-title 121
###xml 33 38 <span type="species:ncbi:9606">human</span>
Revised genomic structure of the human ghrelin gene and identification of novel exons, alternative splice variants and natural antisense transcripts
###end article-title 121
###begin article-title 122
Genome-wide natural antisense transcription: coupling its regulation to its different regulatory mechanisms
###end article-title 122
###begin article-title 123
The transcriptional landscape of the mammalian genome
###end article-title 123
###begin article-title 124
Non-coding RNA
###end article-title 124
###begin article-title 125
A new paradigm for developmental biology
###end article-title 125
###begin article-title 126
###xml 51 56 <span type="species:ncbi:9606">human</span>
Prediction of the coding sequences of unidentified human genes. VI. The coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of cDNA clones from cell line KG-1 and brain
###end article-title 126
###begin article-title 127
GMAP: a genomic mapping and alignment program for mRNA and EST sequences
###end article-title 127
###begin article-title 128
Analysis of canonical and non-canonical splice sites in mammalian genomes
###end article-title 128
###begin article-title 129
Cap analysis gene expression for high-throughput analysis of transcriptional starting point and identification of promoter usage
###end article-title 129
###begin article-title 130
Tag-based approaches for transcriptome research and genome annotation
###end article-title 130
###begin article-title 131
Evolutionary turnover of mammalian transcription start sites
###end article-title 131
###begin article-title 132
Mammalian RNA polymerase II core promoters: insights from genome-wide studies
###end article-title 132
###begin article-title 133
###xml 42 47 <span type="species:ncbi:9606">human</span>
Transcription-mediated gene fusion in the human genome
###end article-title 133
###begin article-title 134
The nonsense-mediated decay RNA surveillance pathway
###end article-title 134
###begin article-title 135
Annotation, submission and screening of repetitive elements in Repbase: RepbaseSubmitter and Censor
###end article-title 135
###begin article-title 136
###xml 39 44 <span type="species:ncbi:9606">human</span>
Initial sequencing and analysis of the human genome
###end article-title 136
###begin article-title 137
###xml 34 39 <span type="species:ncbi:9606">human</span>
Expression of neural BC200 RNA in human tumours
###end article-title 137
###begin article-title 138
Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest
###end article-title 138
###begin article-title 139
Identification and characterization of a novel, psoriasis susceptibility-related noncoding RNA gene, PRINS
###end article-title 139
###begin article-title 140
###xml 62 67 <span type="species:ncbi:9606">human</span>
Identification of a novel gene HEPT3 that is overexpressed in human hepatocellular carcinoma and may function through its noncoding RNA
###end article-title 140
###begin article-title 141
Assembly, organization, and function of the COPII coat
###end article-title 141
###begin article-title 142
The COPII cage: unifying principles of vesicle coat assembly
###end article-title 142
###begin article-title 143
###xml 26 31 <span type="species:ncbi:9606">human</span>
Shotgun sequencing of the human transcriptome with ORF expressed sequence tags
###end article-title 143
###begin article-title 144
###xml 87 93 <span type="species:ncbi:9606">humans</span>
The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans
###end article-title 144
###begin article-title 145
5'-Capping enzymes are targeted to pre-mRNA by binding to the phosphorylated carboxy-terminal domain of RNA polymerase II
###end article-title 145
###begin article-title 146
###xml 38 43 <span type="species:ncbi:10090">mouse</span>
A comprehensive transcript map of the mouse Gnas imprinted complex
###end article-title 146
###begin article-title 147
Identification of a new type of mammalian myosin heavy chain by molecular cloning. Overlap of its mRNA with preprotachykinin B mRNA
###end article-title 147
###begin article-title 148
Constructing the landscape of the mammalian transcriptome
###end article-title 148
###begin article-title 149
Prominent use of distal 5' transcription start sites and discovery of a large number of additional exons in ENCODE regions
###end article-title 149
###begin article-title 150
The multitasking genome
###end article-title 150
###begin article-title 151
###xml 81 104 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Biological function of unannotated transcription during the early development of Drosophila melanogaster
###end article-title 151
###begin article-title 152
A high frequency of overlapping gene expression in compacted eukaryotic genomes
###end article-title 152
###begin article-title 153
###xml 66 71 <span type="species:ncbi:9606">human</span>
Tandem chimerism as a means to increase protein complexity in the human genome
###end article-title 153
###begin article-title 154
###xml 44 49 <span type="species:ncbi:9606">human</span>
Examples of the complex architecture of the human transcriptome revealed by RACE and high-density tiling arrays
###end article-title 154
###begin article-title 155
Genome-wide transcription and the implications for genomic organization
###end article-title 155
###begin article-title 156
The transcriptional landscape of the mammalian genome
###end article-title 156
###begin article-title 157
Alternative trans-splicing: a novel mode of pre-mRNA processing
###end article-title 157
###begin article-title 158
TatD is a cytoplasmic protein with DNase activity. No requirement for TatD family proteins in sec-independent protein export
###end article-title 158
###begin article-title 159
An unappreciated role for RNA surveillance
###end article-title 159
###begin article-title 160
The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers
###end article-title 160
###begin article-title 161
Rapid evolution of noncoding RNAs: lack of conservation does not mean lack of function
###end article-title 161
###begin article-title 162
###xml 69 75 <span type="species:ncbi:9606">humans</span>
An RNA gene expressed during cortical development evolved rapidly in humans
###end article-title 162
###begin article-title 163
###xml 39 44 <span type="species:ncbi:9606">human</span>
Identification and characterization of human non-coding RNAs with tissue-specific expression
###end article-title 163
###begin article-title 164
A novel RNA transcript with antiapoptotic function is silenced in fragile x syndrome
###end article-title 164
###begin article-title 165
Identification and characterization of a novel gene Saf transcribed from the opposite strand of Fas
###end article-title 165
###begin article-title 166
Identification and expression analysis of putative mRNA-like non-coding RNA in Drosophila
###end article-title 166
###begin article-title 167
Increasing biological complexity is positively correlated with the relative genome-wide expansion of non-protein-coding DNA sequences
###end article-title 167
###begin article-title 168
RNA regulation: a new genetics?
###end article-title 168
###begin article-title 169
Non-coding RNAs: the architects of eukaryotic complexity
###end article-title 169
###begin article-title 170
The abundance of short proteins in the mammalian proteome
###end article-title 170
###begin article-title 171
Long, abundantly expressed non-coding transcripts are altered in cancer
###end article-title 171
###begin article-title 172
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
Experimental validation of the regulated expression of large numbers of non-coding RNAs from the mouse genome
###end article-title 172
###begin article-title 173
Clusters of internally primed transcripts reveal novel long noncoding RNAs
###end article-title 173
###begin article-title 174
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
Specific expression of long noncoding RNAs in the mouse brain
###end article-title 174
###begin article-title 175
Noncoding RNAs: couplers of analog and digital information in nervous system function?
###end article-title 175
###begin article-title 176
Non-coding RNAs in the nervous system
###end article-title 176
###begin article-title 177
Noncoding RNAs and RNA editing in brain development, functional diversification, and neurological disease
###end article-title 177
###begin article-title 178
Comparative expression analysis uncovers novel features of endogenous antisense transcription
###end article-title 178
###begin article-title 179
###xml 54 59 <span type="species:ncbi:9606">human</span>
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas
###end article-title 179
###begin article-title 180
An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals
###end article-title 180
###begin article-title 181
Eukaryotic regulatory RNAs: an answer to the 'genome complexity' conundrum
###end article-title 181
###begin article-title 182
The non-coding Air RNA is required for silencing autosomal imprinted genes
###end article-title 182
###begin article-title 183
###xml 65 70 <span type="species:ncbi:9606">human</span>
Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs
###end article-title 183
###begin article-title 184
A strategy for probing the function of noncoding RNAs finds a repressor of NFAT
###end article-title 184
###begin article-title 185
###xml 51 56 <span type="species:ncbi:9606">human</span>
Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR
###end article-title 185
###begin article-title 186
###xml 18 23 <span type="species:ncbi:9606">human</span>
Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript
###end article-title 186
###begin article-title 187
Activation of p53 by MEG3 non-coding RNA
###end article-title 187
###begin article-title 188
MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer
###end article-title 188
###begin article-title 189
Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction
###end article-title 189
###begin article-title 190
A new frontier for molecular medicine: noncoding RNAs
###end article-title 190
###begin article-title 191
Non-coding RNAs: lessons from the small nuclear and small nucleolar RNAs
###end article-title 191
###begin article-title 192
###xml 70 75 <span type="species:ncbi:10090">mouse</span>
Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes
###end article-title 192
###begin article-title 193
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
Endogenous siRNAs from naturally formed dsRNAs regulate transcripts in mouse oocytes
###end article-title 193
###begin article-title 194
###xml 90 95 <span type="species:ncbi:10090">mouse</span>
Organization and transcriptional output of a novel mRNA-like piRNA gene (mpiR) located on mouse chromosome 10
###end article-title 194
###begin article-title 195
RNA maps reveal new RNA classes and a possible function for pervasive transcription
###end article-title 195
###begin article-title 196
Intersection of the RNA interference and X-inactivation pathways
###end article-title 196
###begin article-title 197
In search of antisense
###end article-title 197
###begin article-title 198
###xml 70 76 <span type="species:ncbi:9606">humans</span>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Transcriptional interferences in cis natural antisense transcripts of humans and mice
###end article-title 198
###begin article-title 199
Gene expression from the c-erbA alpha/Rev-ErbA alpha genomic locus. Potential regulation of alternative splicing by opposite strand transcription
###end article-title 199
###begin article-title 200
Post-transcriptional regulation of thyroid hormone receptor expression by cis-acting sequences and a naturally occurring antisense RNA
###end article-title 200
###begin article-title 201
Natural antisense LHCGR could make sense of hypogonadism, male-limited precocious puberty and pre-eclampsia
###end article-title 201
###begin article-title 202
Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene
###end article-title 202
###begin article-title 203
###xml 69 94 <span type="species:ncbi:79674">Macrobrachium rosenbergii</span>
Naturally occurring antisense RNA of allatostatin gene in the prawn, Macrobrachium rosenbergii
###end article-title 203
###begin article-title 204
Mulan: multiple-sequence local alignment and visualization for studying function and evolution
###end article-title 204
###begin article-title 205
ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes
###end article-title 205
###begin article-title 206
The UCSC genome browser database: update 2007 10.1093/nar/gkl928
###end article-title 206
###begin article-title 207
Affymetrix Integrated Genome Browser
###end article-title 207
###begin article-title 208
Genome Network Platform Viewer
###end article-title 208
###begin article-title 209
GNU grep-2.0. Internet Archive: Usenet archive comp. sources.reviewed
###end article-title 209
###begin article-title 210
NCBI ORF Finder
###end article-title 210
###begin article-title 211
Recognition of protein coding regions in DNA sequences
###end article-title 211
###begin article-title 212
TestCode
###end article-title 212
###begin article-title 213
Modeling sequencing errors by combining Hidden Markov models
###end article-title 213
###begin article-title 214
ESTScan: a program for detecting, evaluating, and reconstructing potential coding regions in EST sequences
###end article-title 214
###begin article-title 215
SMART 5: domains in the context of genomes and networks
###end article-title 215
###begin article-title 216
Rolling circle amplification-RACE: a method for simultaneous isolation of 5' and 3' cDNA ends from amplified cDNA templates
###end article-title 216
###begin article-title 217
Co-expression of GH and GHR isoforms in prostate cancer cell lines
###end article-title 217
###begin article-title 218
###xml 48 65 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 155 158 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
A novel strand-specific RT-PCR for detection of hepatitis C virus negative-strand RNA (replicative intermediate): evidence of absence or very low level of HCV replication in peripheral blood mononuclear cells
###end article-title 218
###begin article-title 219
Generation of non-genomic oligonucleotide tag sequences for RNA template-specific PCR
###end article-title 219
###begin article-title 220
Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF
###end article-title 220

